Massive Genetic Study Points to Brain Origins of Fibromyalgia

For decades, fibromyalgia has been difficult to explain biologically, leaving patients and doctors with few clear answers about what causes the widespread pain, fatigue and cognitive symptoms that define the condition. Results of a new study, led by researchers at King’s College London, offer some of the strongest genetic evidence to date that fibromyalgia is rooted in the brain and central nervous system.

Published in Nature Medicine, the study analyzed genetic data from more than 2.5 million adults, including roughly 55,000 people diagnosed with fibromyalgia, pulled from 11 health research cohorts across the United States, United Kingdom, Finland, Estonia, Denmark and Iceland. The research involved 53 investigators across seven countries. By comparing genetic differences between people with and without the condition, the team identified 26 distinct regions of the genome associated with fibromyalgia risk, many of them tied to genes involved in brain and nerve function.

A brain-based condition, genetically confirmed

Fibromyalgia affects roughly 2% of people living in the United States, causing widespread pain, tenderness, fatigue, and difficulties with sleep, memory and mood. Despite its prevalence, its underlying biology has remained murky, in part because it doesn’t show up clearly on standard bloodwork or imaging. This study’s findings help close that gap. The team found that fibromyalgia heritability was concentrated almost entirely in brain tissue and neural cell types, reinforcing the idea that the condition functions as a central nervous system disorder rather than a purely musculoskeletal one.

An unexpected connection to Huntington’s disease

Among the 26 genetic variants identified, the strongest was located within HTT, the gene responsible for Huntington’s disease, a severe and fatal neurodegenerative condition. A second variant pointed to GPR52, a receptor that regulates HTT activity and is already being studied as a potential drug target for Huntington’s disease. Investigators say this overlap, while unexpected, could open new avenues for exploring treatment approaches that might eventually apply to fibromyalgia as well.

Why fibromyalgia rarely travels alone

The study also found strong genetic overlap between fibromyalgia and a range of other chronic pain, psychiatric and somatic conditions, with genetic correlations above 0.7 for low back pain, post-traumatic stress disorder and irritable bowel syndrome. The study’s co-senior investigator, Frances Williams, Ph.D., professor of genomic epidemiology at King’s College London, helped interpret how these genetic patterns align with what clinicians frequently observe: Patients with fibromyalgia often also live with one or more of these other conditions. The team believes shared biological mechanisms within the nervous system may explain why these conditions tend to cluster together in the same patients.

“We know that chronic pain syndromes cluster together in individuals and families and are genetically similar,” said Williams. “Targeting the shared mechanisms underlying them could potentially benefit a whole cluster of disorders.”

Notably, despite fibromyalgia being far more commonly diagnosed in women, the study found the underlying genetic architecture of the condition was nearly identical between men and women, suggesting the prevalence gap likely stems from factors beyond genetics alone.

What this means, and doesn’t mean, for patients

The investigators were clear that these findings do not yet translate into a genetic test for diagnosing fibromyalgia or a new treatment. Genetics also don’t appear to be the sole determinant of who develops the condition. The team suspects that even people carrying multiple fibromyalgia-linked genetic variants may need an additional trigger, such as a painful arthritic condition, for the syndrome to develop.

“Understanding how genes, environmental exposures, and life events jointly contribute to the risk of fibromyalgia syndrome is critical,” noted co-senior investigator Nasa Sinnott-Armstrong, Ph.D., assistant professor at Fred Hutch Cancer Center. “Further research into triggers of fibromyalgia and corresponding changes in neural tissues will help understand what drives fibromyalgia and how to treat it.”

Still, the study represents a significant step toward understanding fibromyalgia’s biological framework. The research team has since founded the Chronic Pain Genomics Consortium to extend this genetic approach to other chronic pain conditions, beginning with pelvic pain, with fibromyalgia serving as an early example of what large-scale genetic research can reveal about conditions that have long lacked clear biological explanations.

“This work changes how we think about fibromyalgia at a fundamental level,” said co-senior investigator Michael Wainberg, Ph.D., an investigator at the Lunenfeld-Tanenbaum Research Institute and the University of Toronto. “For decades, patients have been dismissed or told their pain is simply psychological. Our findings confirm the condition has a clear biological basis.”